Article 1 to 5 out of 5 concerning Roche Diagnostics (Schweiz) AG
454 sequencing at the forefront of bone marrow and stem cell therapy research(01 Jul 2008) Roche Genome Sequencer FLX System creates new opportunities for HLA research at the Blood Centre Linz, Austria The Blood Centre Linz, Austria has purchased a Genome Sequencer FLX System from Roche, for use in research on rejection reactions in Bone Marrow and Stem Cell transplantation. Using conventional Sanger sequencing it can take weeks to analyse large ...
Roche acquires NimbleGen to gain entry into high-growth research microarrray market(21 Jun 2007) Roche and NimbleGen Systems Inc. announced that they have signed a definitive agreement under which Roche will acquire 100% of NimbleGen, a privately held company active in high-density DNA microarrays. Under the terms of the agreement, Roche will ...
Epigenomics reports Tamoxifen treatment response test study results inconclusive(01 Nov 2005) Epigenomics AG announced that following the timely completion of a blinded test study for its Tamoxifen treatment response test, the candidate markers could not be independently validated for technical reasons. The Tamoxifen treatment response test ...
Innogenetics acquires full PCR license from Roche Diagnostics(20 Oct 2005) Innogenetics and Roche Diagnostics announced that they have signed an agreement by which Roche has granted Innogenetics a full, worldwide license for the use of its patented polymerase chain reaction (PCR) technology in the development and ...
Roche and 454 Life Sciences enter exclusive world-wide agreement(12 May 2005) Roche Diagnostics adds ultra-fast nanotechnology-based genome sequencing system to its product portfolio and enters new market sector with significant potentialRoche and 454 Life Sciences, a majority-owned subsidiary of CuraGen Corporation announced ...
Top
